SERPINA1 and diabetes mellitus: Special focus has been placed on α1–antitrypsin (A1AT), the main circulating anti-proteinase inhibitor, which is used as a diabetes therapeutic agent for its broad anti-inflammatory and immune-modulatory properties unrelated to the specific proteinase inhibitory activity7.